Non-Muscle Invasive Bladder Neoplasms: all 273 studies

Page 2 of 3. Open to participants first (117), then studies with results posted, then the rest; newest registration first within each.

• Safety and Efficacy of Scheduled Intravesical Gemcitabine Versus Intravesical BCG for Intermediate and High Risk Non Muscle Invasive Bladder Cancer: A Prospective, Randomized StudyRecruitingNCT05626101Not applicable
• FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3RecruitingNCT05614739Phase 1
• Safety and Efficacy of BCG Combined With Tislelizumab for BCG-untreated Patients With High-risk Non-muscle Invasive Bladder CancerNot yet recruitingNCT05580354Phase 4
• A Phase I Intravesical PPM Therapy for NMIBCRecruitingNCT05519241Phase 1
• Tumor Staging T of Bladder Tumours: Correlation of MRI and Anatomopathologic AnalysisRecruitingNCT05464576Not applicable
• Outpatient Laser Ablation of Recurrent Non-muscle Invasive Bladder CancerRecruitingNCT05337397
• A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder CancerRecruitingNCT05327647Phase 2
• OH2 Oncolytic Viral Therapy in Non-Muscle-Invasive Bladder CancerRecruitingNCT05232136Phase 1/2
• Demonstration of the Medical Interest of the VisioCyt® Artificial Intelligence TestRecruitingNCT05176145Not applicable
• Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard TreatmentRecruitingNCT05126472Phase 1/2
• AFU Registry of the Therapeutic Management and Follow-up of Non-Muscle-Invasive Bladder CancerRecruitingNCT05002556
• LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-NaïveRecruitingNCT04752722Phase 1/2
• A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in naïve Intermediate-risk NMIBC PatientsRecruitingNCT04736394Phase 3
• DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancErRecruitingNCT04106115Phase 1/2
• Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") PatientsRecruitingNCT03945162Phase 2
• Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder CancerRecruitingNCT03379909Phase 2
• Blue Light Cystoscopy With Cysview® RegistryRecruitingNCT02660645
• A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder CancerCompletedNCT06331299Phase 3Results posted
• A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerActive, not recruitingNCT05243550Phase 3Results posted
• Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)CompletedNCT05136898Phase 3Results posted
• Assessment of Safety, Tolerability, Radiation Dosimetry, Imaging Properties of 89Zr-girentuximab in Patients With NMIBCCompletedNCT04897763Early Phase 1Results posted
• LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint InhibitorsTerminatedNCT04690699Phase 1/2Results posted
• A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerTerminatedNCT04688931Phase 3Results posted
• Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder CancerCompletedNCT04496219Phase 2Results posted
• Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder CancerActive, not recruitingNCT04386746Phase 2Results posted
• A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)CompletedNCT04172675Phase 2Results posted
• A Study of Sasanlimab in People With Non-muscle Invasive Bladder CancerActive, not recruitingNCT04165317Phase 3Results posted
• CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder CancerActive, not recruitingNCT03933826Results posted
• Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder CancerCompletedNCT03892642Phase 1/2Results posted
• Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBCTerminatedNCT03719300Phase 2Results posted
• A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder CancerCompletedNCT03558503Phase 2Results posted
• Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)TerminatedNCT03167151Phase 1/2Results posted
• Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder CancerCompletedNCT03081858Phase 1/2Results posted
• Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder CancerCompletedNCT02844816Phase 2Results posted
• Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder CancerCompletedNCT02808143Phase 1Results posted
• Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) ParticipantsTerminatedNCT02792192Phase 1/2Results posted
• ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)CompletedNCT02773849Phase 3Results posted
• A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance SettingCompletedNCT02560584Phase 3Results posted
• Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCGCompletedNCT02449239Phase 3Results posted
• CAVATAK (CVA21) in Non-muscle Invasive Bladder Cancer (VLA-012 CANON)CompletedNCT02316171Phase 1Results posted
• A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBTTerminatedNCT02010203Phase 1/2Results posted
• Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder CancerCompletedNCT02009332Phase 1/2Results posted
• A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder CancerTerminatedNCT01625260Phase 1/2Results posted
• Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)TerminatedNCT01469221Phase 3Results posted
• Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder CancerTerminatedNCT01410565Phase 3Results posted
• Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the BladderTerminatedNCT01310803Phase 3Results posted
• Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder CancerTerminatedNCT01200992Phase 3Results posted
• Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer PatientsTerminatedNCT00974818Phase 3Results posted
• Age and Bladder Cancer Outcomes After BCG Treatment: A Multicenter StudyCompletedNCT07798479
• Predictive Value of E-cadherin, β-catenin and SOX4 in Recurrence and/or Progression of Non-muscle Invasive Urinary Bladder Transitional Cell Carcinoma. A Retrospective StudyCompletedNCT07657299
• ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder CancerWithdrawnNCT07551544Phase 3
• BladMetrix Urine Test for Monitoring Recurrence in Non-Muscle Invasive Bladder CancerActive, not recruitingNCT07511517
• A Phase I-II Study of Novel Oncolytic Virus VG161 Via Intravesical Instillation for BCG-Unresponsive Non-Muscle-Invasive Bladder CancerCompletedNCT07505615Phase 1/2
• CRUCIAL-R Study : Cruciferous Vegetables Dietary Regimen in NMIBCActive, not recruitingNCT07391137Not applicable
• Comparison of Pathological Outcome and Recurrence Rate Between En Bloc and Conventional Transurethral Resection of Bladder TumorCompletedNCT07347132Not applicable
• A Study of Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBTWithdrawnNCT07313891Phase 3
• The Role of Universal Cancer Only Marker SIX6 in Diagnosing Non-Muscle Invasive Bladder CancerActive, not recruitingNCT07252297Not applicable
• Pre-Approval Expanded Access Study for TAR-200 Treating Physician UseApproved for marketingNCT06877676
• Thulium Laser En-bloc Resection of Primary Non-muscle Invasive Bladder CancerCompletedNCT06818799Not applicable
• A Study to Evaluate Eciskafusp Alfa in Combination With Bacillus Calmette-guerin (BCG) in Participants With BCG-unresponsive High-risk Non-muscle Invasive Bladder Cancer (NMIBC)WithdrawnNCT06816017Phase 1
• Comparison of BCG RIVM and Russian Strains for Treating Non-Muscle-Invasive Bladder Cancer (NMIBC)CompletedNCT06767982Phase 4
• BCG + MMC: Adding Mitomycin C to BCG in High-risk, Non-muscle-invasive Bladder CancerActive, not recruitingNCT06462001Phase 3
• Study of CG0070 After Transurethral Resection in Patients With IR NMIBCActive, not recruitingNCT06253845Phase 1
• Biomarkers of Recurrence and Progression in Non-muscle Invasive Bladder CancerCompletedNCT06235853
• A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)Active, not recruitingNCT06211764Phase 3
• Predictors of Residual Tumor at Second Transurethral Resection for pT1 Non-muscle Invasive Bladder CancerCompletedNCT06205277
• Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder CancerActive, not recruitingNCT06187506Phase 2
• A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder CancerCompletedNCT06181266Phase 1
• Urine-based Molecular Testing vs Cystoscopy for Surveillance of Nonmuscle Invasive Bladder Cancer (NMIBC)CompletedNCT06126796
• A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBTActive, not recruitingNCT06111235Phase 3
• Hyaluronic Acid Sodium Salt and Hydeal-D in the Management of LUTS After TURBT for NMIBC.TerminatedNCT06069453Not applicable
• ADSTILADRIN Early Utilization and Outcomes in the Real World SettingTerminatedNCT06026332
• Analytical Specificity of Bladder EpiCheck Test in Healthy Population and Urology Patients Without Prior History or Evidence of Bladder CancerCompletedNCT06020807
• Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)Active, not recruitingNCT05981131
• Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder CancerCompletedNCT05946369
• Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDERCompletedNCT05945108
• BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC ParticipantsActive, not recruitingNCT05943106Phase 3
• External Validation of Uromonitor as a Biomarker for Optimization of NMIBC Management by the CUETO GroupActive, not recruitingNCT05864599
• The Effect of Telephone-Assisted Smoking Cessation Program in Patients Diagnosed With Non-Muscle Invasive Bladder CancerStatus unknownNCT05704231Not applicable
• Antegrade Observational Comparative Study for the Intravesical Instillation Therapy of Bacillus Calmette Guerin With the Use of Different Types of Urinary Catheters in Patients With Urinary Bladder CancerCompletedNCT05675176
• Gemcitabine and Docetaxel Therapy in High-risk BCG-naive Patients With Non-muscle Invasive Bladder CancerActive, not recruitingNCT05671900Not applicable
• Oncolytic Adenovirus Combined With PD-1 Inhibitor in Patients With Non-muscle-invasive Bladder CancerStatus unknownNCT05564897Phase 2
• Blue Laser -5ala Photodynamic Therapy (PDT) in High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) PatientsStatus unknownNCT05547516Not applicable
• Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene AlterationsActive, not recruitingNCT05544552Phase 1/2
• Intravesical BCG vs GEMDOCE in NMIBCActive, not recruitingNCT05538663Phase 3
• A Performance Evaluation Study of Arquer's MCM5 Elisa Test (ADXBLADDER) to Aid in the Monitoring of Recurrence in Non-Muscle Invasive Bladder CancerStatus unknownNCT05508568
• A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder CancerActive, not recruitingNCT05483868Phase 1
• A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)CompletedNCT05375903Phase 1
• Machine Learning-Based Prediction of BCG Response in High-Risk Non-Muscle Invasive Bladder Cancer PatientsStatus unknownNCT05332353
• Study of Erdafitinib Intravesical Delivery System for Localized Bladder CancerActive, not recruitingNCT05316155Phase 1/2
• High-power Green-light Laser Endoscopic Submucosal Dissection for Non-muscle-invasive Bladder CancerCompletedNCT05290623
• PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)WithdrawnNCT05259397Phase 1
• En Bloc Transurethral Resection of Non-muscle Invasive Bladder CancerCompletedNCT05223491Not applicable
• Optimal Adjuvant Intravesical Therapy for Intermediate Risk Non Muscle Invasive Bladder Cancer: A Randomized Controlled TrialStatus unknownNCT05146635Not applicable
• Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder CancerWithdrawnNCT05120622Phase 1/2
• Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1b)CompletedNCT05085990Phase 1
• Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a)CompletedNCT05085977Phase 1
• A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)TerminatedNCT05014139Phase 1
• Clinical and Functional Consequences of Photodynamic Diagnosis (PDD) and Intravesical Instillation TherapyActive, not recruitingNCT04943094
• A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder CancerActive, not recruitingNCT04917809Phase 2

← Non-Muscle Invasive Bladder Neoplasms overview